CNS Pharmaceuticals, Inc. entered into a warrant exercise inducement offer letter with a holder of certain existing warrants to receive new warrants to purchase up to 200% of the number of warrant shares issued pursuant to the exercise of such certain existing warrants to purchase shares of common stock, in exchange for the Company's agreement to issue the Inducement Warrants to purchase up to 3,756,000 shares of the Company's common stock. The Company anticipates receiving aggregate gross proceeds of up to approximately $2.4 million from the exercise of the Existing Warrants before deducting financial advisory fees and other expenses payable by it.